Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Shandong Weigao Group Medical Polymer Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

Potential Transaction

The board of directors of the Company (the "**Board**") hereby announces that on 17 October 2025 (after trading hours), the Company, Weihai Shengxi Enterprise Management Consulting Center (Limited Partnership)*(威海盛熙企業管理諮詢中心(有限合夥), "**Weihai Shengxi**"), Weihai Ruiming Enterprise Management Consulting Partnership (Limited Partnership)*(威海瑞明企業管理諮詢合夥企業(有限合夥), "**Weihai Ruiming**", together with the Company and Weihai Shengxi, the "**WEGO Prefills Shareholders**"), and Shandong Weigao Blood Purification Products Co., Ltd.*(山東威高血液淨化製品股份有限公司, "**Weigao Blood Purification**") entered into a non-legally binding letter of intent (the "**Letter of Intent**"), pursuant to which Weigao Blood Purification intends to acquire 100% equity interest in Shandong WEGO Prefills Pharmaceutical Packaging Co., Ltd. *(山東威高普瑞醫藥包裝有限公司, "**WEGO Prefills**") by issuing consideration shares to each of the WEGO Prefills Shareholders (the "**Potential Transaction**"). The Letter of Intent only reflects the preliminary understanding among the parties regarding the Potential Transaction. The terms and conditions of the Potential Transaction are subject to further negotiation and the signing of definitive transaction documents. As at the date of this announcement, the Parties have not entered into any legally binding definitive agreement.

Reasons for and Benefits of the Potential Transaction

Weigao Blood Purification is a company incorporated in China whose A shares are listed on the Shanghai Stock Exchange (stock code: 603014.SH). It is primarily engaged in the businesses of research and development, production, and sales of medical products for blood purification. Its main products include hemodialyzers, hemodialysis tubing sets, hemodialysis machines, and peritoneal dialysis solutions, covering both hemodialysis and peritoneal dialysis fields, supplemented by the sales of supporting dialysis products. As at the date of this announcement, Weigao Blood Purification is controlled by Weigao Holding Co., Ltd.*(威高集團有限公司), a controlling shareholder of the Company. The Company also directly holds 23.53% of the shares of Weigao Blood Purification.

WEGO Prefills focuses on the research and development, production, and sales of pharmaceutical packaging materials such as pre-filled drug delivery systems and automatic safety drug delivery systems. It is committed to providing one-stop drug delivery solutions for global biopharmaceutical companies. As at the date of this announcement, WEGO Prefills is a non-wholly owned subsidiary of the Company, held as to 94.0706%, 4.0215%, and 1.9078% by the Company, Weihai Shengxi, and Weihai Ruiming, respectively.

The Board considers that, if the Potential Transaction is completed, WEGO Prefills and Weigao Blood Purification will generate business synergies, and the overall business scope of the Group will be further expanded.

Implications under the Listing Rules

As at the date of this announcement, both the Company and Weigao Blood Purification are ultimately controlled by Mr. Chen Xueli. Therefore, Weigao Blood Purification is a connected person of the Company. If the Potential Transaction proceeds, it may constitute a major transaction under Chapter 14 and a connected transaction under Chapter 14A of the Listing Rules. The Company will disclose the transaction details in accordance with the Listing Rules in due course.

The Potential Transaction may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

17 October 2025
Weihai, Shandong, the PRC

As at the date of this announcement, the Board comprises:

Mr. Long Jing *(Executive Director)*
Mr. Cong Rinan *(Executive Director)*
Mr. Lu Junqiang *(Executive Director)*
Mr. Wang Daoming *(Executive Director)*
Mr. Chen Lin *(Non-executive Director)*
Mr. Tang Zhengpeng *(Non-executive Director)*
Mr. Li Guohui *(Independent Non-executive Director)*
Mrs. Meng Hong *(Independent Non-executive Director)*
Mr. Li Qiang *(Independent Non-executive Director)*
Mr. Sun Heng *(Independent Non-executive Director)*

* *For identification purposes only*